Glaukos Co. (NYSE:GKOS) Insider Tomas Navratil Sells 3,416 Shares

Glaukos Co. (NYSE:GKOS) insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Glaukos Stock Performance

GKOS stock opened at $126.03 on Friday. The business’s fifty day moving average is $152.75 and its 200-day moving average is $139.25. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market cap of $6.95 billion, a P/E ratio of -41.73 and a beta of 1.04. Glaukos Co. has a twelve month low of $83.90 and a twelve month high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Equities research analysts forecast that Glaukos Co. will post -1.89 EPS for the current year.

Institutional Trading of Glaukos

Several hedge funds have recently added to or reduced their stakes in the business. State of Wyoming raised its stake in Glaukos by 2.3% during the 4th quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier’s stock worth $487,000 after buying an additional 72 shares during the period. Quadrant Capital Group LLC raised its stake in Glaukos by 3.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier’s stock worth $345,000 after buying an additional 73 shares during the period. Mutual of America Capital Management LLC raised its stake in shares of Glaukos by 1.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock valued at $1,252,000 after purchasing an additional 89 shares during the period. HighTower Advisors LLC raised its stake in shares of Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock valued at $495,000 after purchasing an additional 91 shares during the period. Finally, Louisiana State Employees Retirement System raised its stake in shares of Glaukos by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Wells Fargo & Company boosted their price objective on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $132.00 to $162.00 in a research report on Wednesday, December 11th. Stifel Nicolaus boosted their price objective on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. BTIG Research boosted their price objective on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Finally, UBS Group started coverage on Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.